207729-05-3

Basic information

• Product Name: Carbamic acid, (3-cyclopenten-1-ylmethyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (3-cyclopenten-1-ylmethyl)-, 1,1-dimethylethyl ester (9CI)
• CAS NO: 207729-05-3
• Molecular Formula: C11H19NO2
• Molecular Weight: 197.27406
• Product Categories: N-BOC
• Mol File: 207729-05-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Carbamic acid, (3-cyclopenten-1-ylmethyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (3-cyclopenten-1-ylmethyl)-, 1,1-dimethylethyl ester (9CI)(207729-05-3)
• EPA Substance Registry System: Carbamic acid, (3-cyclopenten-1-ylmethyl)-, 1,1-dimethylethyl ester (9CI)(207729-05-3)

Safety Data

• Hazardous Substances Data: 207729-05-3(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 4492-42-6 (cyclopent-3-ene)methylamine 
• 7686-77-3 3-cyclopentene-1-carboxylic acid 
• 25125-21-7 4-(hydroxymethyl)cyclopentene 
• 321386-75-8 methanesulfonic acid cyclopent-3-enylmethyl ester 
• 1364687-10-4 C₆H₉N₃ 

Relevant articles and documents

Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes

Compounds selected from the group ofN-unsubstituted or N-alkylated or N-acylated 14-O-[(amino(C0-4)alkyl-hydroxy-cycloalkyl- or bicycloalkylsulfanyl)-acetyl]-mutilins which are 14-O-[(amino(C0-4)alkyl-hydroxy-cyclobutylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C0-4)alkyl-hydroxy-cyclopentylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C0-4)alkyl-hydroxy-cycloheptylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C0-4)alkyl-hydroxy-cyclooctylsulfanyl)-acetyl]-mutilins, or 14-O-[(amino(C0-4)alkyt-hydroxy-bicycloalkylsulfanyl)-acetyl]-mutilins, optionally in the form of a salt and/or a solvate, a pharmaceutical compositions comprising such compounds and their use as pharmaceuticals, e.g. for the treatment of microbial infections and for the treatment of acne, optionally in combination with other pharmaceutically active agents.

PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES

Compounds selected from the group of N-unsubstituted or N-alkylated or N-acylated 14-O-[(amino(C0-4)alkyl-hydroxy-cycloalkyl- or bicycloalkylsulfanyl)-acetyl]-mutilins which are 14-O-[(amino(C0-4)alkyl-hydroxy-cyclobutylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C0-4)alkyl-hydroxy-cyclopentylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C0-4)alkyl-hydroxy- cycloheptylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C0-4)alkyl-hydroxy-cyclooctylsulfanyl)- acetyl]-mutilins, or 14-O-[(amino(C0-4)alkyl-hydroxy-bicycloalkylsulfanyl)-acetyl]-mutilins, optionally in the form of a salt and/or a solvate, a pharmaceutical compositions comprising such compounds and their use as pharmaceuticals, e.g. for the treatment of microbial infections and for the treatment of acne, optionally in combination with other pharmaceutically active agents.

On the possibility of carbamate-directed hydroboration. An approach to the asymmetric synthesis of 1-aminocyclopentane-1,3-dicarboxylic acid

Hydroboration (using BH3) of 1-substituted 3-cyclopentenes 3, 9 and 17 and an enantioselective synthesis of the excitatory amino acid 1- aminocyclopentane-1,3-dicarboxylic acid via asymmetric hydroboration [90% de, 45% ee using (+)-IpcBH2] of cyclopentene 17 are described.